Adiponectin/leptin ratio predicts the remission of metabolic syndrome : A pilot study
Copyright © 2024. Published by Elsevier B.V..
BACKGROUND: Adipokines are key mediators of inflammation in metabolic syndrome perpetuating the effect of excess nutrient intake by setting a self-maintaining vicious circle. Here, we assess levels of adiponectin and leptin in a cohort of individuals with MetS undergoing dietary and behavioral counselling. Specifically, we investigate their role as predictors of metabolic syndrome remission after 1 year.
METHODS: Patients with MetS (n = 127) received behavioral and dietary recommendations and were followed-up for 1 year. Serum was available for 108 individuals, levels of adiponectin and leptin were tested at baseline, at 6 months (t1) and after 1 year (t2). Adiponectin/leptin (A/L) ratio was also calculated and tested for predictive ability.
RESULT: At the end of the follow-up period, 59 patients did not show enough criteria to define MetS anymore. When considered alone, adiponectin and leptin levels did not show difference over follow-up. Their ratio instead was significantly reduced at t1 and t2 with respect to baseline. Remitters also showed lowers level of leptin and A/L ratio as compared to non-remitters at t1. At this timepoint, A/L ratio independently predicted MetS remission at 1 year [OR 9.082 95%CI (1.394-59.160), p = 0.021]. Bootstrap resampling analysis internally validated our findings.
CONCLUSIONS: Preliminary results from our pilot study suggest that MetS remission after counselling associates with changes in adipokine balance. A/L ratio decreases overtime and its value at 6 months can independently predict MetS remission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:400 |
|---|---|
| Enthalten in: |
International journal of cardiology - 400(2024) vom: 01. Feb., Seite 131791 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liberale, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adipocytokine |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijcard.2024.131791 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367353784 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367353784 | ||
| 003 | DE-627 | ||
| 005 | 20240220232238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2024.131791 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM367353784 | ||
| 035 | |a (NLM)38244890 | ||
| 035 | |a (PII)S0167-5273(24)00121-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liberale, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adiponectin/leptin ratio predicts the remission of metabolic syndrome |b A pilot study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Adipokines are key mediators of inflammation in metabolic syndrome perpetuating the effect of excess nutrient intake by setting a self-maintaining vicious circle. Here, we assess levels of adiponectin and leptin in a cohort of individuals with MetS undergoing dietary and behavioral counselling. Specifically, we investigate their role as predictors of metabolic syndrome remission after 1 year | ||
| 520 | |a METHODS: Patients with MetS (n = 127) received behavioral and dietary recommendations and were followed-up for 1 year. Serum was available for 108 individuals, levels of adiponectin and leptin were tested at baseline, at 6 months (t1) and after 1 year (t2). Adiponectin/leptin (A/L) ratio was also calculated and tested for predictive ability | ||
| 520 | |a RESULT: At the end of the follow-up period, 59 patients did not show enough criteria to define MetS anymore. When considered alone, adiponectin and leptin levels did not show difference over follow-up. Their ratio instead was significantly reduced at t1 and t2 with respect to baseline. Remitters also showed lowers level of leptin and A/L ratio as compared to non-remitters at t1. At this timepoint, A/L ratio independently predicted MetS remission at 1 year [OR 9.082 95%CI (1.394-59.160), p = 0.021]. Bootstrap resampling analysis internally validated our findings | ||
| 520 | |a CONCLUSIONS: Preliminary results from our pilot study suggest that MetS remission after counselling associates with changes in adipokine balance. A/L ratio decreases overtime and its value at 6 months can independently predict MetS remission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adipocytokine | |
| 650 | 4 | |a Adiponectin | |
| 650 | 4 | |a Adiponectin/leptin ratio | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Leptin | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 7 | |a Leptin |2 NLM | |
| 650 | 7 | |a Adiponectin |2 NLM | |
| 650 | 7 | |a Adipokines |2 NLM | |
| 700 | 1 | |a Carbone, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Bonaventura, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Kraler, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolotto, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Artom, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Pontremoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Viazzi, Francesca C |e verfasserin |4 aut | |
| 700 | 1 | |a Pende, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Pisciotta, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Montecucco, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cardiology |d 1984 |g 400(2024) vom: 01. Feb., Seite 131791 |w (DE-627)NLM012621196 |x 1874-1754 |7 nnns |
| 773 | 1 | 8 | |g volume:400 |g year:2024 |g day:01 |g month:02 |g pages:131791 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijcard.2024.131791 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 400 |j 2024 |b 01 |c 02 |h 131791 | ||